Q1 FY27 results analysis · August 05, 2026

Shilpa Medicare Ltd (SHILPAMED) Q1 FY27 Results Analysis: Revenue Surges 44.89%, EBITDA Margin Expands 226 bps

+115.2%PAT year on year, Rs. 100.88 Cr
Cofacto ResearchPublished August 05, 20262 min readPositive read
Quick summary

Shilpa Medicare Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 465.78 Cr (+44.89% YoY) and PAT growth of +115.19% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 05, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 465.78 Cr (+44.89% YoY)
PAT (Q1)Rs. 100.88 Cr (+115.19% YoY)
EBITDA margin30.54% (+226 bps YoY)
EPS (Q1)Rs. 5.16 (+115.00% YoY)
Market capRs. 14,034.48 Cr
CMPRs. 721.75

Quarter Snapshot

Revenue grew 44.89% YoY with EBITDA margin expanding 226 bps, driven by operating leverage and cost management. PAT more than doubled, though a one-time deferred tax reversal inflated reported earnings. The strong operational momentum is positive, but the employee cost spike and absence of explicit guidance limit conviction.

Key Investment Insights

Key Positives

  • Revenue grew 44.89% YoY to Rs.465.78 Cr, the highest Q1 print in the visible trajectory.
  • EBITDA margin expanded 226 bps YoY to 30.54%, reflecting operating leverage as costs grew slower than revenue.
  • PAT grew 115.19% YoY to Rs.100.88 Cr; normalized PAT of Rs.74.04 Cr still grew 57.9% YoY.
  • Finance costs fell 35.57% YoY to Rs.12.10 Cr, a significant positive surprise versus the expected headwind.
  • Cost of materials consumed grew only 25.64% YoY, much slower than revenue, indicating favorable product mix.

Risk Factors

  • Employee benefits expense jumped 15.19% QoQ to Rs.99.71 Cr, which needs monitoring if it persists.
  • Reported PAT was inflated by a one-time deferred tax reversal of Rs.26.84 Cr; normalized PAT is Rs.74.04 Cr.
  • The company received a Form 483 with 5 observations at Unit VI, though VAI status is maintained.
  • The STPL merger creates comparability noise for YoY analysis, as standalone revenue doubled partly due to the merger.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.